News

Adlai Nortye Reduces IPO Size

1 Mins read

Adlai Nortye, a biotechnology company, is adjusting its initial public offering (IPO) to decrease its investment in program development. According to a Securities and Exchange Commission filing on Wednesday, the company is reducing the number of American depositary shares offered from 3 million to 2.5 million.

Previously, Adlai Nortye had indicated a price range of $22 to $26 per share. However, the estimated price per share for the IPO will now be $23. As a result of these changes, the company expects net proceeds of $54.2 million instead of the initially projected $67.9 million.

Out of the revised amount, Adlai Nortye plans to allocate $29.7 million towards its pipeline of programs and $13.5 million towards general working and corporate purposes. This differs from their previous plan in August, which aimed to invest $41.5 million in program development and $15.5 million for corporate purposes.

Despite the adjustments to their IPO, Adlai Nortye remains committed to investing $46.7 million in funding the registrational trial for the AN2025 inhibitor, as well as milestone payments for its development and commercial launch if approved.

Related posts
News

Solana Holds Near $236 As Whale Staking Builds Pressure At Resistance (SOL-USD)

1 Mins read
Whales staked more than $1.5 billion in SOL, reducing circulating supply. Solana (SOL-USD) is trading around $235.87, consolidating after briefly touching $237…
News

A'Court dismisses appeal against citizens' right to public information

2 Mins read
The Court of Appeal sitting in Abuja has delivered two landmark judgments affirming citizens’ right to access public information, dismissing separate appeals…
News

15 ransomware gangs 'go dark' to enjoy 'golden parachutes'

4 Mins read
PLUS: China’s Great Firewall springs a leak; FBI issues rare ‘Flash Alert’ of Salesforce attacks; $10m bounty for alleged Russian hacker; and…

Leave a Reply

Your email address will not be published. Required fields are marked *